Linda Woodson, MD
Dermatology · Las Vegas, NVNPI 1972682664
Payments from drug & device makers
Across 620 payments — averaging $34.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$10K
- AbbVie$3K
- Johnson & Johnson$1K
- Journey Medical Corporation$916
- Sun Pharmaceutical Industries Inc.$825
- Pfizer$734
- plus $5K from 30 others
What the payments were for
- Consulting fees$7,80036%
- Travel & lodging$1,3356%
- Food & beverage$11,43453%
- Education$9484%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 22 | $9,755 |
| AbbVie(2 entities) | 147 | $2,855 |
| Johnson & Johnson | 68 | $1,412 |
| Journey Medical Corporation | 8 | $916 |
| Sun Pharmaceutical Industries Inc. | 34 | $825 |
| Pfizer | 50 | $734 |
| E.r. Squibb & Sons, L.L.C. | 67 | $662 |
| Novartis | 28 | $566 |
| Lilly USA, LLC | 22 | $564 |
| Sanofi | 27 | $489 |
| Galderma Laboratories, L.p. | 31 | $430 |
| Dermavant Sciences, Inc. | 25 | $405 |
| Merz North America, Inc. | 8 | $323 |
| Amgen | 9 | $184 |
| Incyte Corporation | 8 | $151 |
| VYNE Pharmaceuticals Inc. | 2 | $134 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 7 | $123 |
| Bristol Myers Squibb | 16 | $120 |
| Almirall LLC | 6 | $117 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| LEO Pharma Inc. | 5 | $88 |
| Sandoz | 4 | $84 |
| Regeneron Healthcare Solutions, Inc. | 3 | $82 |
| Arcutis Biotherapeutics, Inc. | 3 | $57 |
| Organon | 3 | $54 |
| Genentech USA, Inc. | 3 | $48 |
| Dermira, Inc. | 2 | $41 |
| Verrica Pharmaceuticals Inc. | 2 | $37 |
| Helsinn Therapeutics (U.S.), Inc. | 2 | $31 |
| Boehringer Ingelheim | 1 | $26 |
| Botanix SB Inc | 1 | $23 |
| EPI Health, LLC | 1 | $21 |
| Organogenesis Inc. | 1 | $17 |
| Medimetriks Pharmaceuticals, Inc. | 1 | $16 |
| Melinta Therapeutics, LLC | 1 | $14 |
| Encore Dermatology Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$21,516 in reported general payments places this provider in the 85th percentile of 78 dermatology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 38 | $593,005 |
| TremfyaGuselkumab | 12 | $162,385 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 16 | $122,662 |
| Dupixent SyringeDupilumab | 26 | $92,047 |
| Dupixent PenDupilumab | 22 | $82,241 |
| OtezlaApremilast | 13 | $67,559 |
| OpzeluraRuxolitinib Phosphate | 19 | $38,348 |
| Tacrolimus | 49 | $6,941 |
| Betamethasone Dipropionate | 125 | $5,191 |
| Clobetasol Propionate | 157 | $3,690 |
| Fluorouracil | 48 | $2,923 |
| Triamcinolone Acetonide | 241 | $2,584 |
| Fluocinonide | 78 | $2,387 |
| Azelaic Acid | 16 | $2,131 |
| Doxycycline Hyclate | 81 | $1,452 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonTremfya | $1,412 | $162,38512 claims |
| AmgenOtezla | $184 | $67,55913 claims |
| Incyte CorporationOpzelura | $151 | $38,34819 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 78 dermatology providers in Nevada.
Other dermatology in Las Vegas
- Harry GreenbergLas Vegas$1.5M
- David CotterLas Vegas$1.5M
- Victoria FarleyLas Vegas$956K
- Miriam BettencourtLas Vegas$772K
- Candace SpannLas Vegas$18K
- Clifton HallLas Vegas$16K
- Jason StevensLas Vegas$15K
- Lionel HandlerLas Vegas$14K
- Frank RuecklLas Vegas$11K
- Susun MichaelsLas Vegas$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.